Perspective Therapeutics, Inc. filed a Current Report on Form 8-K dated September 8, 2026, to update its corporate presentation. The filing includes a copy of the presentation as Exhibit 99.1, which details preliminary clinical data for three alpha-particle (alpha-Pb) radiopharmaceutical programs.
The presentation outlines the company's strategy to develop the most potent payloads in targeted oncology, targeting a combined addressable market of over $45 billion in solid tumors. The three clinical-stage programs discussed are:
- VMT-α-NET: A potential first-in-class 212Pb radioligand therapy targeting SSTR2 for neuroendocrine tumors. The company reported ongoing Phase 1/2a data analysis from ASCO 2026, noting that best responses deepen over time and durable disease control was observed across all dose levels. The presentation states that the safety profile supports the potential for a registration study at the current dose level.
- VMT01: A potential first-in-class 212Pb therapy targeting MC1R for melanoma. The company is conducting an open-label Phase 1/2a trial. Preliminary anti-tumor activity was observed at a dose of 3.0 mCi, and the company indicated that clinical data supports further development.
- PSV359: A potential first-in-class 212Pb therapy targeting FAP-α for advanced solid tumors. The company is running an open-label Phase 1/2a trial and reported that the agent has improved tumor retention.
The company also discussed its platform and manufacturing capabilities, including structural chemistry optimization, the selection of isotopes, and a strategy for direct-to-hospital delivery through integrated isotope production. The filing highlights a strong intellectual property portfolio covering the radiopharmaceutical value chain.
